Researchers at Brigham and Women’s Hospital and Beth-Israel Deaconess Medical Center, both in Boston, have discovered a biomarker that can be used to identify people who may develop kidney cancer. Called kidney-injury-molecule-1 (KIM-1), the marker is normally present at low levels in blood and urine.
The researchers measured KIM-1 in people enrolled in the European Prospective Investigation into Cancer and Nutrition. They compared levels in 190 participants who developed kidney cancer (also called renal cell carcinoma, or RCC) within five years to those of 190 participants matched for age, body mass index (BMI), smoking status, and other factors who didn’t develop kidney cancer. They found that KIM-1 levels were twice as high in those who developed RCC.
According to the Boston researchers, KIM-1 testing doubles the accuracy of current screening tests used to measure kidney disease biomarkers and could allow for the earlier detection of kidney cancer.
Sourced from: Clinical Cancer Research